Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.

Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.

Item
http://www.wikidata.org/entity/Q40286999
Keyhole limpet haemocyanin - a model antigen for human immunotoxicological studiesPrediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation.A novel immunomodulatory hemocyanin from the limpet Fissurella latimarginata promotes potent anti-tumor activity in melanoma.Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.Bladder cancer in 2012: Challenging current paradigms.Current intravesical therapy for non-muscle invasive bladder cancer.Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer.Mycobacterium phlei cell wall-nucleic acid complex in the treatment of nonmuscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.Quality of transurethral resection of bladder tumor procedure influenced a phase III trial comparing the effect of KLH and mitomycin C.Truncated Escherichia coli thioredoxin induces proliferation of human blood mononuclear cells and production of reactive oxygen species as well as proinflammatory cytokines.Alternative therapies in patients with non-muscle invasive bladder cancer.The efficacy of Apaziquone in the treatment of bladder cancer.Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
P2860

Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial.

Item
http://www.wikidata.org/entity/Q40286999
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Intracutaneous and intravesica ...... ve randomized phase III trial.
@en
type
label
Intracutaneous and intravesica ...... ve randomized phase III trial.
@en
prefLabel
Intracutaneous and intravesica ...... ve randomized phase III trial.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Intracutaneous and intravesica ...... ve randomized phase III trial.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921